Core Viewpoint - Kohl's (KSS) is expected to report quarterly earnings of $0.33 per share, reflecting a 44.1% decline year-over-year, with revenues forecasted at $3.48 billion, a decrease of 6.9% compared to the previous year [1]. Earnings Projections - The consensus EPS estimate has been revised upward by 2.9% in the last 30 days, indicating analysts' reassessment of their initial estimates [1][2]. - Prior revisions to earnings projections are crucial for predicting investor behavior regarding the stock [2]. Revenue Estimates - Analysts predict 'Other revenue' to reach $180.61 million, down 12.8% year-over-year [4]. - Estimated 'Net Sales' are projected at $3.34 billion, indicating a decline of 5.3% from the previous year [4]. - 'Revenue Recognition- Accessories' is expected to be $699.10 million, showing a 5% increase from the prior-year quarter [4]. Segment Revenue Forecasts - 'Revenue Recognition- Children's' is estimated at $326.53 million, down 9% from the year-ago quarter [5]. - 'Revenue Recognition- Footwear' is projected at $259.36 million, reflecting a 19% decline year-over-year [5]. - 'Revenue Recognition- Men's' is expected to reach $725.15 million, indicating a 2% decrease from the previous year [5]. - 'Revenue Recognition- Women's' is forecasted at $950.37 million, down 5.3% year-over-year [6]. - 'Revenue Recognition- Home' is estimated at $421.80 million, showing a 3.3% decline from the prior year [6]. Store Metrics - The consensus estimate for the total number of stores stands at 1,153, compared to 1,100 a year ago [6]. Stock Performance - Kohl's shares have returned -2.3% over the past month, contrasting with the Zacks S&P 500 composite's +1.1% change [6].

Core Viewpoint - BioLife Solutions, Inc. (BLFS) has received an upgrade to a Zacks Rank 1 (Strong Buy) due to an upward trend in earnings estimates, indicating a positive outlook for the company's stock price [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in buying or selling pressure that affects stock prices [4]. Company Performance Indicators - BioLife Solutions is expected to earn $0.05 per share for the fiscal year ending December 2025, with no year-over-year change [8]. - Over the past three months, the Zacks Consensus Estimate for BioLife Solutions has increased by 150%, reflecting a significant positive revision in earnings estimates [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - The upgrade of BioLife Solutions to Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, indicating strong potential for market-beating returns in the near term [10].

The company is expanding its go-to-market strategies with a growing pipeline and positive customer feedback on value creation through risk mitigation, water savings and enhanced comfort. In 2025, Watts Water aims to further scale its digital solutions ecosystem. The company's margin performance is also benefiting from aggressive cost reduction actions. This maker of valves for plumbing, heating and water needs is expected to post quarterly earnings of $2.68 per share in its upcoming report, which represents ...

Core Viewpoint - Wall Street analysts predict Carpenter Technology (CRS) will report quarterly earnings of $2.03 per share, reflecting an 11.5% year-over-year increase, while revenues are expected to decline by 3.6% to $770.22 million [1]. Earnings Estimates - The consensus EPS estimate has been revised 0.4% lower over the last 30 days, indicating a collective reevaluation by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, with empirical studies showing a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue and Sales Projections - Analysts estimate 'Net Sales- End-Use Market Excluding Surcharge Revenue- Total' at $629.98 million, a decrease of 0.9% from the prior year [5]. - The estimate for 'Net Sales- End-Use Market Excluding Surcharge Revenue- Surcharge revenue' is $139.64 million, indicating a 14.3% decline year-over-year [5]. - 'Net Sales- Performance Engineered Products' is projected at $110.82 million, down 0.4% from the previous year [6]. - 'Net Sales- Specialty Alloys Operations' is expected to reach $685.66 million, reflecting a 4.2% decrease year-over-year [6]. Volume and Operating Income Estimates - 'Volumes Sold in Pounds - Specialty Alloys Operations' are projected to be 47.04 million, down from 57.20 million in the same quarter last year [7]. - 'Volumes Sold in Pounds' overall is expected to be 48.80 million, compared to 56.78 million in the same quarter of the previous year [7]. - 'Operating Income- Performance Engineered Products' is forecasted at $11.14 million, up from $10.60 million in the same quarter last year [8]. - The consensus for 'Operating Income- Specialty Alloys Operations' stands at $163.52 million, compared to $140.90 million a year ago [8]. Stock Performance - Carpenter shares have changed by +0.2% in the past month, compared to a +4.9% move of the Zacks S&P 500 composite [8]. - With a Zacks Rank 2 (Buy), CRS is expected to outperform the overall market in the near future [8].

Core Viewpoint - Mind Medicine (MindMed) Inc. has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Ratings - The Zacks rating system is based on changes in earnings estimates, which are tracked through the Zacks Consensus Estimate from sell-side analysts for the current and following years [2]. - The recent upgrade reflects an improvement in MindMed's earnings outlook, which could lead to increased buying pressure and a rise in stock price [4][6]. Impact of Institutional Investors - Changes in a company's future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements, largely due to institutional investors adjusting their valuations based on these estimates [5]. - An increase in earnings estimates typically results in higher fair value for a stock, prompting institutional investors to buy or sell accordingly, which influences stock price movements [5]. Earnings Estimate Revisions for MindMed - For the fiscal year ending December 2025, MindMed is expected to earn -$1.48 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 4.3% over the past three months [9]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [8]. - MindMed's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10][11].